Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Core Insights - The company is focused on innovative approaches in the field of in vivo CAR-T therapy, emphasizing its unique position in a competitive landscape [1] - The primary asset of interest is SC451, aimed at providing a functional cure for type 1 diabetes, a condition affecting approximately 9 million individuals [2] Company Overview - The company was founded on two main ideas: evading immune detection of cells and delivering specific payloads to targeted cells in vivo [2] - The development of SC451 is a significant focus, indicating the company's commitment to addressing unmet medical needs in diabetes treatment [2]